Collaborative Drug Discovery Receives New Funding to Support Tuberculosis Drug Discovery Screening Efforts and Industrial-Academic Collaborations

BURLINGAME, Calif., Jan. 13, 2011 /PRNewswire/ — Collaborative Drug Discovery, Inc. (CDD) today announced that the Bill & Melinda Gates Foundation has extended its previous grant to CDD to create a novel database to spark collaborative efforts to discover more effective drugs against tuberculosis (TB). The TB bacillus infects approximately one third of the world’s population and the disease kills over 1.5 million people every year.

Over the past two years, the CDD TB database has integrated the efforts of academic, non-profit, government and corporate laboratories distributed across the globe to accelerate their efforts to discover new therapies against this deadly disease.

Over the next three years, CDD will play a critical role in facilitating collaborations among leading TB researchers — now including three large pharmaceutical companies — aimed at advancing the best drug prospects. CDD will focus its powerful archiving, mining, and collaboration capabilities on supporting the workflows of screening centers searching to identify better drug leads that can be turned into more effective therapies for TB. CDD will help these collaborations work smoothly by securely sharing data among the labs and providing additional bioinformatics services to catalyze drug discovery.

“For six years CDD has focused on supporting humanitarian as well as commercial drug discovery. Now we are excited to put our new CDD Projects technology to the test. CDD Projects enables natural yet secure real-time collaborations among researchers that mimics the way people work in the pharmaceutical industry,” said Barry Bunin, PhD, CEO & President of CDD.

“This project has enabled the creation of a unique database of well over 300,000 molecules with screening data against Mycobacterium tuberculosis,” said Sean Ekins, PhD, Director of Collaborations. “We have also collected literature data and patent information for many compounds and freely shared this data with the research community. In addition we have enabled many groups to store and share their small molecule screening data, securely over the Internet ‘in the cloud’ using unique proprietary technologies.”

The foundation’s supplement extends the project to five years and increases the total grant to $2,796,000.

More information about the CDD TB database work and related updates can be found here.

About Collaborative Drug Discovery, Inc.

CDD hosts the most widely-used drug discovery cloud platform on the market. CDD Vault offers a private, secure industrial-strength database combining traditional drug discovery informatics (registration and SAR) with social networking capabilities. CDD Collaborate enables real-time collaboration by securely exchanging selected confidential data with external researchers. CDD Public provides free access to data that researchers have deposited in the public domain. CDD Projects enables easy management of multiple collaborations. For more information about CDD, visit www.collaborativedrug.com.

For further information please contact:

Barry Bunin, Ph.D.
President & CEO
Collaborative Drug Discovery (CDD), Inc.
1633 Bayshore Hwy, Suite 342,
Burlingame, CA 94010
Tel: +1 650 204 3084
Email: info@collaborativedrug.com

This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities!

CDD Vault: Drug Discovery Informatics your whole project team will embrace!